Citigroup Issues Pessimistic Forecast for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX) had its price objective reduced by research analysts at Citigroup from $7.00 to $6.25 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective indicates a potential upside of 37.97% from the company’s current price.

A number of other research analysts have also recently commented on the company. KeyCorp decreased their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday. Mizuho assumed coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, November 11th. Finally, Morgan Stanley dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.38.

GoodRx Trading Up 5.8 %

Shares of GDRX stock traded up $0.25 on Friday, hitting $4.53. 1,259,145 shares of the stock traded hands, compared to its average volume of 1,230,036. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx has a twelve month low of $4.09 and a twelve month high of $9.26. The firm’s 50-day moving average price is $4.75 and its two-hundred day moving average price is $6.59. The stock has a market capitalization of $1.73 billion, a PE ratio of -151.00, a PEG ratio of 3.43 and a beta of 1.27.

Institutional Trading of GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in GoodRx in the 3rd quarter valued at about $33,000. Plato Investment Management Ltd purchased a new stake in shares of GoodRx during the 2nd quarter worth $43,000. EP Wealth Advisors LLC purchased a new position in shares of GoodRx in the 3rd quarter valued at about $73,000. Sanctuary Advisors LLC acquired a new stake in shares of GoodRx in the third quarter valued at about $85,000. Finally, Dark Forest Capital Management LP purchased a new stake in GoodRx during the second quarter worth about $86,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.